Lissandra Dal Lago

2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial

Aron Goldhirsch, Richard D. Gelber, Martine Piccart et al. · The Lancet · 2013 · 498 citations

Breast Oncology, Health Sciences, Medicine +7

Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program

Fátima Cardoso, John M.S. Bartlett, Leen Slaets et al. · Annals of Oncology · 2017 · 381 citations · Full text

Eortc 10085/Tbcrc/big/nabcg, Breast Oncology, Medicine +7

Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group

Hans Wildiers, Konstantinos Tryfonidis, Lissandra Dal Lago et al. · The Lancet Oncology · 2018 · 126 citations

Breast Oncology, Oncology, Metronomic Therapy +7

TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial

Hervé Bonnefoi, Martine Piccart, Jan Bogaerts et al. · The Lancet Oncology · 2011 · 125 citations · Full text

Tp53 Status, Breast Oncology, Medicine +7

Characteristics and prognosis of stage I-III breast cancer subtypes in Brazil: The AMAZONA retrospective cohort study

Sérgio D. Simon, José Bines, Gustavo Werutsky et al. · The Breast · 2019 · 112 citations

Breast Oncology, Cancer Epidemiology, Medicine +6